Estimated extent of cross-resistance to ritonavir-boosted protease inhibitors among protease inhibitors-experienced patients: Implications for tipranavir use

被引：4

作者：

Gallego, O ^{[1
]}

De Mendoza, C ^{[1
]}

Corral, A ^{[1
]}

Barrios, A ^{[1
]}

Soriano, V ^{[1
]}

机构：

[1] Hosp Carlos III, Infect Dis Serv, Madrid, Spain

来源：

AIDS PATIENT CARE AND STDS | 2005年 / 19卷 / 02期

关键词：

D O I：

10.1089/apc.2005.19.67

中图分类号：

R1 [预防医学、卫生学];

学科分类号：

1004 ; 120402 ;

摘要：

引用

页码：67 / 69

页数：3

共 14 条

[1] In-vitro tipranavir susceptibility of HIV-1 isolates with reduced susceptibility to other protease inhibitors [J].

Back, NKT ;

van Wijk, A ;

Remmerswaal, D ;

van Monfort, M ;

Nijhuis, M ;

Schuurman, R ;

Boucher, CAB .

AIDS, 2000, 14 (01) :101-102

[2] Comparison of the efficacy, safety and predictive value of HIV genotyping using distinct ritonavir-boosted protease inhibitors [J].

Barreiro, P ;

Camino, N ;

de Mendoza, C ;

Valer, L ;

Núñez, M ;

Martín-Carbonero, L ;

González-Lahoz, J ;

Soriano, V .

INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2002, 20 (06) :438-443

[3] A retrospective, cohort-based survey of patients using twice-daily indinavir plus ritonavir combinations: Pharmacokinetics, safety, and efficacy [J].

Burger, DM ;

Hugen, PWH ;

Aarnoutse, RE ;

Dieleman, JP ;

Prins, JM ;

van der Poll, T ;

ten Veen, JH ;

Mulder, JW ;

Meenhorst, PL ;

Blok, WL ;

van der Meer, JTM ;

Reiss, P ;

Lange, JMA .

JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2001, 26 (03) :218-224

[4]

de Mendoza Carmen, 2002, HIV Clin Trials, V3, P304

[5] HIV INHIBITORY NATURAL-PRODUCTS .7. THE CALANOLIDES, A NOVEL HIV-INHIBITORY CLASS OF COUMARIN DERIVATIVES FROM THE TROPICAL RAIN-FOREST TREE, CALOPHYLLUM-LANIGERUM [J].

KASHMAN, Y ;

GUSTAFSON, KR ;

FULLER, RW ;

CARDELLINA, JH ;

MCMAHON, JB ;

CURRENS, MJ ;

BUCKHEIT, RW ;

HUGHES, SH ;

CRAGG, GM ;

BOYD, MR .

JOURNAL OF MEDICINAL CHEMISTRY, 1992, 35 (15) :2735-2743

[6] Identification of genotypic changes in human immunodeficiency virus protease that correlate with reduced susceptibility to the protease inhibitor lopinavir among viral isolates from protease inhibitor-experienced patients [J].

Kempf, DJ ;

Isaacson, JD ;

King, MS ;

Brun, SC ;

Xu, Y ;

Real, K ;

Bernstein, BM ;

Japour, AJ ;

Sun, E ;

Rode, RA .

JOURNAL OF VIROLOGY, 2001, 75 (16) :7462-7469

[7] Tipranavir inhibits broadly protease inhibitor-resistant HIV-1 clinical samples [J].

Larder, BA ;

Hertogs, K ;

Bloor, S ;

van den Eynde, C ;

DeCian, W ;

Wang, YY ;

Freimuth, WW ;

Tarpley, G .

AIDS, 2000, 14 (13) :1943-1948

[8]

MCCALLISTER S, 2003, ANTIVIR THER S, V8, P15

[9]

POSTEL N, 2003, 9 EUR AIDS C WARS PO

[10]

SQUIRES K, 2003, ANTIVIR THER S, V8, P412

← 1 2 →